MURRAY HILL, N.J.--(BUSINESS WIRE)--Nov. 8, 2007--C. R. Bard, Inc.
(NYSE: BCR) today announced that it has received clearance from the
United States Food and Drug Administration to market its Agento(TM) IC
silver-coated endotracheal tube. The clearance includes claims for the
reduction of microbiologically confirmed ventilator associated
pneumonia (VAP). Management is currently evaluating the benefits of
launching the Agento(TM) IC product in conjunction with the potential
publication of the clinical trial results in a major peer-review
medical journal. The product will be marketed by Bard's Medical
division located in Covington, Georgia.
VAP is one of the most costly hospital acquired infections and is
associated with high patient mortality and morbidity. It is especially
prevalent in hospital intensive care units in cases where a ventilated
patient has an endotracheal tube in place for more than 24 hours. The
Agento(TM) IC product incorporates Bard's proprietary silver colloid
polymer technology which allows the tube to elute microbicidal levels
of silver ions.
C. R. Bard, Inc., (www.crbard.com) headquartered in Murray Hill,
N.J., is a leading multinational developer, manufacturer and marketer
of innovative, life-enhancing medical technologies in the fields of
vascular, urology, oncology and surgical specialty products.
This press release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995,
which are based on management's current expectations, the accuracy of
which is necessarily subject to risks and uncertainties. These
statements are not historical in nature and use words such as
"anticipate", "estimate", "expect", "project", "intend", "forecast",
"plan", "believe", and other words of similar meaning in connection
with any discussion of future operating or financial performance. Many
factors may cause actual results to differ materially from anticipated
results including product developments, sales efforts, income tax
matters, the outcomes of contingencies such as legal proceedings, and
other economic, business, competitive and regulatory factors. The
company undertakes no obligation to update its forward-looking
statements. Please refer to the Cautionary Statement Regarding
Forward-Looking Information in our September 30, 2007 Form 10-Q/A for
more detailed information about these and other factors that may cause
actual results to differ materially from those expressed or implied.
CONTACT: C. R. Bard, Inc.
Eric J. Shick
Vice President, Investor Relations
Holly P. Glass
Vice President, Government and Public Relations
SOURCE: C. R. Bard, Inc.